

# Lisa Zimmer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4157997/publications.pdf>

Version: 2024-02-01

145  
papers

11,101  
citations

71102

41  
h-index

33894

99  
g-index

151  
all docs

151  
docs citations

151  
times ranked

15575  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015, 350, 207-211.	12.6	2,275
2	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1087-1095.	10.7	841
3	The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. <i>Cancer Discovery</i> , 2014, 4, 94-109.	9.4	782
4	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 190-209.	2.8	546
5	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019, 25, 1916-1927.	30.7	541
6	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 210-225.	2.8	490
7	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , 2016, 45, 7-18.	7.7	354
8	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	2.8	269
9	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , 2017, 57, 36-49.	7.7	257
10	Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. <i>Journal of Clinical Oncology</i> , 2012, 30, 2375-2383.	1.6	216
11	TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	204
12	Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. <i>PLoS ONE</i> , 2015, 10, e0118564.	2.5	197
13	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2020, 395, 1558-1568.	13.7	188
14	Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 12-23.	2.8	171
15	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. <i>European Journal of Cancer</i> , 2017, 75, 24-32.	2.8	162
16	Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. <i>European Journal of Cancer</i> , 2017, 75, 47-55.	2.8	145
17	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. <i>ESMO Open</i> , 2019, 4, e000491.	4.5	140
18	TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. <i>Modern Pathology</i> , 2014, 27, 502-508.	5.5	108

#	ARTICLE	IF	CITATIONS
19	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
20	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2021, 22, 836-847.	10.7	104
21	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. European Journal of Cancer, 2018, 104, 137-144.	2.8	97
22	Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management. Archives of Dermatology, 2012, 148, 357.	1.4	96
23	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunology, Immunotherapy, 2018, 67, 825-834.	4.2	91
24	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. European Journal of Cancer, 2020, 130, 126-138.	2.8	84
25	Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. European Heart Journal, 2022, 43, 316-329.	2.2	84
26	Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	1.6	83
27	Checkpoint Inhibitors. Deutsches Arzteblatt International, 2019, 116, 119-126.	0.9	83
28	SF3B1 and BAP1 mutations in blue nevus-like melanoma. Modern Pathology, 2017, 30, 928-939.	5.5	81
29	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Modern Pathology, 2014, 27, 175-183.	5.5	78
30	TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma. PLoS ONE, 2013, 8, e80354.	2.5	78
31	Failure to detect production of IL-10 by activated human neutrophils. Nature Immunology, 2011, 12, 1017-1018.	14.5	70
32	Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations. Oncotarget, 2017, 8, 40683-40692.	1.8	69
33	Management of side effects of immune checkpoint blockade by anti-CTLA4 and anti-PD1 antibodies in metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 662-681.	0.8	63
34	Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. European Journal of Cancer, 2017, 86, 248-256.	2.8	63
35	MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series. Cancer Immunology, Immunotherapy, 2019, 68, 983-990.	4.2	62
36	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS/RAF Mutations. Clinical Cancer Research, 2014, 20, 4251-4261.	7.0	60

#	ARTICLE	IF	CITATIONS
37	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 351.	4.4	56
38	Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. <i>Journal of Neuro-Oncology</i> , 2016, 127, 435-444.	2.9	55
39	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. , 2020, 8, e000333.		55
40	Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. <i>European Journal of Cancer</i> , 2020, 131, 18-26.	2.8	50
41	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
42	Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. <i>European Journal of Cancer</i> , 2019, 119, 18-29.	2.8	44
43	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2019, 110, 11-20.	2.8	44
44	Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. <i>European Journal of Cancer</i> , 2020, 138, 125-132.	2.8	44
45	BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. <i>Chinese Clinical Oncology</i> , 2014, 3, 29.	1.2	44
46	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. , 2020, 8, e000897.		40
47	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 147, 170-181.	2.8	40
48	The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. <i>European Journal of Cancer</i> , 2021, 155, 268-280.	2.8	37
49	Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis. <i>Medicine (United States)</i> , 2016, 95, e4332.	1.0	35
50	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. <i>British Journal of Cancer</i> , 2018, 118, 785-792.	6.4	34
51	Clinical and genetic analysis of melanomas arising in acral sites. <i>European Journal of Cancer</i> , 2019, 119, 66-76.	2.8	34
52	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	1.6	33
53	The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 73-87.	2.4	32
54	Phase 1b/2 trial of ribociclib+binimetinib in metastatic <i>NRAS</i> -mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9519-9519.	1.6	32

#	ARTICLE	IF	CITATIONS
55	Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity. <i>Journal of Clinical Oncology</i> , 2013, 31, 3844-3845.	1.6	30
56	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	2.8	28
57	Lack of SF3B1 R625 mutations in cutaneous melanoma. <i>Diagnostic Pathology</i> , 2013, 8, 87.	2.0	27
58	Complete remission of metastatic melanoma upon BRAF inhibitor treatment – what happens after discontinuation?. <i>Melanoma Research</i> , 2015, 25, 362-366.	1.2	27
59	Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. <i>Melanoma Research</i> , 2019, 29, 65-69.	1.2	27
60	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	6.4	27
61	Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. <i>European Journal of Cancer</i> , 2014, 50, 406-410.	2.8	26
62	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10005-10005.	1.6	26
63	Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9527-9527.	1.6	25
64	PLX4032: does it keep its promise for metastatic melanoma treatment?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1439-1449.	4.1	24
65	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 582-609.	0.8	24
66	Isolated cerebral susceptibility artefacts in patients with malignant melanoma: metastasis or not?. <i>European Radiology</i> , 2013, 23, 2622-2627.	4.5	21
67	Side effects of systemic oncological therapies in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 475-486.	0.8	20
68	Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 816-823.	1.6	20
69	Nebenwirkungen onkologischer Systemtherapien in der Dermatologie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 475-487.	0.8	19
70	Conjunctival Melanomas Harbor <i>BRAF</i> and <i>NRAS</i> Mutations – Response. <i>Clinical Cancer Research</i> , 2013, 19, 6331-6332.	7.0	19
71	SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry. <i>European Journal of Cancer</i> , 2021, 144, 382-385.	2.8	18
72	Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 396-398.	5.0	18

#	ARTICLE	IF	CITATIONS
73	Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <i>NRAS</i> -mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3002-3010.	7.0	18
74	Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2018, 7, 95-104.	2.8	16
75	Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study. <i>Journal of Dermatology</i> , 2020, 47, 629-635.	1.2	16
76	Leptomeningeal disease from melanoma – Poor prognosis despite new therapeutic modalities. <i>European Journal of Cancer</i> , 2021, 148, 395-404.	2.8	16
77	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 148, 61-75.	2.8	15
78	Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. <i>Cancers</i> , 2021, 13, 2319.	3.7	15
79	The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series. <i>Journal of Clinical Oncology</i> , 2018, 36, e21588-e21588.	1.6	15
80	Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival. <i>International Journal of Cancer</i> , 2016, 139, 1297-1302.	5.1	14
81	Oncogene status as a diagnostic tool in ocular and cutaneous melanoma. <i>European Journal of Cancer</i> , 2016, 57, 112-117.	2.8	14
82	Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?. , 2019, 7, 141.		14
83	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. <i>European Journal of Cancer</i> , 2021, 153, 168-178.	2.8	14
84	Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. <i>European Journal of Cancer</i> , 2021, 158, 72-84.	2.8	14
85	CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. <i>New England Journal of Medicine</i> , 2022, 386, 1668-1669.	27.0	14
86	Aktuelle Fortschritte und Ausblicke in der Therapie des metastasierten Melanoms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 319-325.	0.8	13
87	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. <i>European Journal of Cancer</i> , 2021, 152, 139-154.	2.8	13
88	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 159, 113-124.	2.8	13
89	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021, 151, 72-83.	2.8	12
90	Quality of medical care of patients with acne vulgaris in Germany – nationwide survey of pharmacy clients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 1060-1063.	0.8	11

#	ARTICLE	IF	CITATIONS
91	<i>IRF4</i> rs12203592 functional variant and melanoma survival. International Journal of Cancer, 2017, 140, 1845-1849.	5.1	11
92	Trametinib-Induced Remission of an <i>MEK1</i>-Mutated Langerhans Cell Histiocytosis. JCO Precision Oncology, 2017, 1, 1-5.	3.0	11
93	Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology. PLoS Pathogens, 2020, 16, e1008340.	4.7	11
94	Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanomaâ€”A Retrospective Multicenter ADOReg Study. Cancers, 2021, 13, 2312.	3.7	11
95	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. European Journal of Cancer, 2021, 156, 149-163.	2.8	11
96	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy â€” A multicentre study of 90 patients from the German Dermat oncology Group. European Journal of Cancer, 2021, 149, 1-10.	2.8	10
97	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition â€” A Descriptive Observational Retrospective Multicenter Analysis. Frontiers in Oncology, 2021, 11, 765608.	2.8	10
98	TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. European Journal of Cancer, 2022, 161, 99-107.	2.8	10
99	Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. , 2020, 8, e000395.		9
100	Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. ENeurologicalSci, 2021, 22, 100324.	1.3	9
101	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. Frontiers in Oncology, 2021, 11, 741993.	2.8	9
102	Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection. PLoS ONE, 2015, 10, e0124590.	2.5	9
103	Analysis of SDHD promoter mutations in various types of melanoma. Oncotarget, 2015, 6, 25868-25882.	1.8	9
104	Patterns of disease control and survival in patients withÂ melanoma brain metastases undergoing immune-checkpoint blockade. European Journal of Cancer, 2018, 99, 58-65.	2.8	8
105	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. Clinical Cancer Research, 2021, 27, 4500-4510.	7.0	8
106	Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. , 2022, 10, e004509.		8
107	Prognostic factors for pulmonary metastasectomy in malignant melanoma: size matters. European Journal of Cardio-thoracic Surgery, 2019, 56, 1104-1109.	1.4	7
108	Re-induction ipilimumab following acquired resistance to combination ipilimumab and antiâ€”PD-1 therapy. European Journal of Cancer, 2021, 153, 213-222.	2.8	7



#	ARTICLE	IF	CITATIONS
109	Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. <i>European Journal of Cancer</i> , 2022, 166, 60-72.	2.8	7
110	Health services research in dermatology ? current update and perspectives. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 482-487.	0.8	6
111	Dose-dependent toxicity of ipilimumab in metastatic melanoma. <i>European Journal of Cancer</i> , 2018, 95, 104-108.	2.8	6
112	Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 592609.	2.8	6
113	ECG Changes in Melanoma Patients Undergoing Cancer Therapy—Data from the ECoR Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 2060.	2.4	6
114	Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition — Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry. <i>Frontiers in Oncology</i> , 2021, 11, 725549.	2.8	6
115	Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10016-10016.	1.6	6
116	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
117	Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology. <i>European Journal of Cancer</i> , 2021, 148, 340-347.	2.8	5
118	Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival. <i>Cancers</i> , 2022, 14, 2090.	3.7	5
119	Gebrauch von Komplementärmedizin bei Patienten mit metastasierendem Melanom unter Therapie mit Ipilimumab innerhalb einer klinischen Studie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 508-513.	0.8	4
120	Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. <i>European Journal of Cancer</i> , 2017, 83, 142-145.	2.8	4
121	Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9532-9532.	1.6	4
122	The nature and management of acquired resistance to PD1-based therapy in melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10014-10014.	1.6	4
123	The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3324.	4.1	4
124	Reply to M. Perier-Muzet et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3203-3204.	1.6	3
125	Use of complementary medicine in metastatic melanoma patients treated with ipilimumab within a clinical trial. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 508-513.	0.8	3
126	Radiosensitization by BRAF inhibitors. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 703-708.	0.8	3



#	ARTICLE	IF	CITATIONS
127	Sebaceous tumours: more than skin deep. <i>Gut</i> , 2018, 67, 1957-1957.	12.1	2
128	Fatal swelling of the groin " Clear cell sarcoma: a rare but important differential diagnosis to malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1165-1168.	0.8	2
129	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1763-1771.	2.5	2
130	Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 637185.	2.8	2
131	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. <i>Frontiers in Oncology</i> , 2021, 11, 672172.	2.8	2
132	Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases. <i>European Journal of Cancer</i> , 2021, 150, 119-129.	2.8	2
133	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma " Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e343-e344.	10.7	2
134	Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9031-9031.	1.6	2
135	Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9545-9545.	1.6	2
136	BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9008-9008.	1.6	2
137	Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma. <i>Cancer Imaging</i> , 2022, 22, 11.	2.8	2
138	Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors. <i>International Journal of Cancer</i> , 0, , .	5.1	2
139	Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report. <i>BMC Cancer</i> , 2019, 19, 995.	2.6	1
140	Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. <i>European Journal of Cancer</i> , 2021, 143, 43-45.	2.8	1
141	Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9533-9533.	1.6	1
142	The genetic landscape of clinical resistance to RAF inhibition in melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11009-11009.	1.6	1
143	BRAF/MEK inhibition in melanoma patients with rare BRAF mutations.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9542-9542.	1.6	1
144	Metastatic pigmented epithelioid melanocytoma in a 7-year-old female. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1217-1219.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP).. Journal of Clinical Oncology, 2016, 34, 9558-9558.	1.6	0